Campbell & Co Investment Adviser’s Emergent Biosolutions EBS Stock Holding History

Campbell & Co Investment Adviser’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,386	Closed	-$161K	–	1113
2026 Q1	$161K	Sell	19,386 -81,118	-81%	-$840K	0.01%	978
2025 Q4	$1.24M	Buy	100,504 +55,896	+125%	+$599K	0.06%	479
2025 Q3	$393K	Buy	+44,608	New	+$347K	0.03%	816
2025 Q2	–	Sell	-21,240	Closed	-$103K	–	1206
2025 Q1	$103K	Buy	+21,240	New	+$176K	0.01%	984
2024 Q4	–	Sell	-47,717	Closed	-$398K	–	1124
2024 Q3	$398K	Buy	+47,717	New	+$434K	0.03%	802
2023 Q3	–	Sell	-16,272	Closed	-$120K	–	1004
2023 Q2	$120K	Buy	+16,272	New	+$151K	0.02%	837
2022 Q1	–	Sell	-5,050	Closed	-$220K	–	744
2021 Q4	$220K	Sell	5,050 -2,900	-36%	-$131K	0.08%	502
2021 Q3	$398K	Buy	+7,950	New	+$481K	0.13%	286
2019 Q4	–	Sell	-8,311	Closed	-$434K	–	689
2019 Q3	$434K	Buy	+8,311	New	+$387K	0.16%	228
2017 Q1	–	Sell	-6,434	Closed	-$211K	–	167
2016 Q4	$211K	Buy	+6,434	New	+$193K	0.65%	85

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

OHA

Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Campbell & Co Investment Adviser's EBS Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Emergent Biosolutions (EBS) in Q2 2026, closing a stake of 19,386 shares — an estimated $161K sold.

Campbell & Co Investment Adviser first reported a position in EBS in Q4 2016 and held it in 10 quarters. The position peaked at $1.24M in Q4 2025. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

Campbell & Co Investment Adviser reported no remaining Emergent Biosolutions position as of Q2 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 19,386 Emergent Biosolutions shares in Q2 2026, an estimated $161K.
Campbell & Co Investment Adviser first reported a position in Emergent Biosolutions in Q4 2016 and held it in 10 quarters.
Campbell & Co Investment Adviser's Emergent Biosolutions position peaked at $1.24M in Q4 2025.
194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.